Compare ELAN & TPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ELAN | TPG |
|---|---|---|
| Founded | 1954 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.3B | 8.9B |
| IPO Year | 2018 | 2022 |
| Metric | ELAN | TPG |
|---|---|---|
| Price | $22.38 | $65.19 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 13 |
| Target Price | $23.11 | ★ $67.00 |
| AVG Volume (30 Days) | ★ 6.1M | 1.6M |
| Earning Date | 11-05-2025 | 02-10-2026 |
| Dividend Yield | N/A | ★ 2.66% |
| EPS Growth | N/A | ★ N/A |
| EPS | 0.07 | ★ 0.10 |
| Revenue | ★ $4,591,000,000.00 | $4,255,344,000.00 |
| Revenue This Year | $7.19 | N/A |
| Revenue Next Year | $5.32 | $27.41 |
| P/E Ratio | ★ $313.80 | $670.85 |
| Revenue Growth | 3.08 | ★ 24.91 |
| 52 Week Low | $8.02 | $37.52 |
| 52 Week High | $23.70 | $70.11 |
| Indicator | ELAN | TPG |
|---|---|---|
| Relative Strength Index (RSI) | 55.09 | 60.93 |
| Support Level | $21.95 | $64.16 |
| Resistance Level | $22.57 | $66.52 |
| Average True Range (ATR) | 0.62 | 1.82 |
| MACD | 0.05 | -0.15 |
| Stochastic Oscillator | 86.40 | 53.10 |
Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, goats, and swine production.
TPG Inc is an alternative asset management firm. It invests across five multi-product platforms namely Capital, Growth, Impact, Real Estate, Market Solutions, and TPG Angelo Gordon. The company focuses on large-scale, control-oriented private equity investments.